Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-11
2008-03-11
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S212080, C544S284000, C540S524000
Reexamination Certificate
active
07342022
ABSTRACT:
The present invention relates to new compounds of formula I wherein R1, R2, R3, n, m are defined as in claim 1, a process for their preparation and new intermediates used in the preparation thereof, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3
REFERENCES:
patent: 6265411 (2001-07-01), Thomas et al.
patent: 6294532 (2001-09-01), Thomas et al.
patent: 7205314 (2007-04-01), Berg et al.
patent: 2005/0070559 (2005-03-01), Berg et al.
patent: 2005/0075351 (2005-04-01), Berg et al.
patent: 1136493 (2001-09-01), None
patent: WO-95/33750 (1995-12-01), None
patent: WO-97/42187 (1997-11-01), None
patent: WO-99/10349 (1999-03-01), None
patent: WO-00/10975 (2000-03-01), None
Piyasena Hewawasam et al., “Synthesis and Structure-Activity Relationships of 3-Arylosindoles: A new Class of Calcium-Dependent, Large Conductance Potassium (Maxi-K) Channel Openers with Neuroprotective Properties”. J. Med. Chem., vol. 45, 2002, pp. 1487-1499.
Imahori and Uchida., Physiology and Pathology of Tau Protein Kinases in Relation to Alzheimer'Disease. J. Biochem 121, 1997, pp. 179-188.
Hoshi et al., “Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3β in brain”, PNAS vol. 93, Apr. 1996, pp. 2719-2723.
Bhat et al., “Regulation and localization of tyrosine216phosphorylation of glycogen synthase kinase-3β in cellular and animal models of neuronal degeneration”, PNAS vol. 97, No. 20, Sep. 2000, pp. 11074-11079.
Stambolic et al., “Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells”, Current Biol. 1996, vol. 6, pp. 1664-1668.
Klein and Melton, “A molecular mechanism for the effect of lithium on development”, Proc. Natl. Acad. Sci. USA, vol. 93, Aug. 1996, pp. 8455-8459.
Kozlovsky et al., “Low GSK-3β Immunoreactivity in Postmortem Frontal Cortex of Schizophrenic Patients”, Am. J. Psychiatry, May 2000, vol. 157(5), pp. 831-833.
Cotter et al., Abnormalities of Wnt signalling in schizophrenia-evidence for neurodevelopmental abnormality, NeuroReport, vol. 9, May 1998, pp. 1379-1383.
Nikoulina et al., “Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance if type 2 diabetes”, Diabetes, vol. 49, Feb. 2000, pp. 263-271.
Gat et al., “De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated β-Catenin in Skin”, Cell, vol. 95, Nov. 1998, pp. 605-614.
Vijajaraghavan et al., “Role for Phosphorylation of Glycogen Synthase Kinase-3α in Bovine Sperm Motility Regulation”, Biol. Reprod. vol. 62 Jan. 2000, pp. 1647-1654.
Berg Stefan
Bhat Ratan
Edwards Philip
Hellberg Sven
Astrazeneca AB
Bernhardt Emily
Truong Tamthom N.
LandOfFree
Compounds in the treatment of dementia related diseases,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds in the treatment of dementia related diseases,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds in the treatment of dementia related diseases,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2785962